CHF Solutions Offers Educational Event on Effective Fluid Management Strategies in Heart Failure Patients
January 21 2021 - 8:00AM
CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to
changing the lives of patients suffering from fluid overload, today
announced the company will host an interactive, physician-led
webinar to discuss “Real-World Experience Using Ultrafiltration in
the Management of Heart Failure Patients.” The virtual event will
take place on Wednesday, January 27 at 11 a.m. Central
Time.
The webinar panelists include:
- Robert A. Watson III, MD, FAAC,
Chief, Cardiology Division, Co-Director, Comprehensive Heart
Failure Program at Abington Jefferson Health, Pennsylvania
- Donald C. Haas, MD, Medical
Director, Ventricular Assist Device Program; Co-Director,
Comprehensive Heart Failure Program at Abington Jefferson Health,
Pennsylvania
- Maureen Hummel, CRNP, Clinical
Director, Comprehensive Heart Failure Program at Abington Jefferson
Health, Pennsylvania
- Patti Barrella, MSN, CHFN, Heart
Failure Coordinator at Abington Jefferson Health, Pennsylvania
- John L. Jefferies, Jay M. Sullivan
Distinguished Chair in Cardiovascular Medicine and Chief of
Cardiology at the University of Tennessee Health Science
Center
90% of the nearly 1 million annual heart failure
hospitalizations in the U.S. are due to signs and symptoms of fluid
overload.1,2,Volume regulation and management are key components to
the treatment of heart failure patients.3 Mechanical
ultrafiltration (UF), such as the Aquadex™ technology, has been
used successfully to treat heart failure patients suffering from
fluid overload. Data recently published in the Journal of Cardiac
Failure Supplement demonstrated UF with Aquadex is a safe and
effective strategy for decongestion and compares favorably in
reducing heart failure rehospitalizations, renal function response,
and weight/volume loss. The panelists from Abington Jefferson
Health can provide unique perspective on the data as authors of the
study.
Those interested in attending the educational webinar can
register through this link. For those unable to attend the webinar,
an archive of the webcast will be available within 48 hours after
the event concludes on the CHF Solutions’ YouTube channel. and CHF
Solutions’ website.
1. Costanzo MR, et al. J Am Coll Cardiol. 2007 Feb 13;
49(6): 675-683.
2. Gheorghiade M, Filippatos G. Eur Heart J. 2005 Mar 15; 7
(Suppl): B13-B19.
3. Miller WL. Circ Heart Fail.206;9:e002922-31
About CHF Solutions CHF
Solutions, Inc. (Nasdaq: CHFS) is a medical device company
dedicated to improving the lives of patients suffering from fluid
overload with its novel ultrafiltration therapy system. The company
is focused on developing, manufacturing and commercializing the
Aquadex SmartFlow system for ultrafiltration therapy. CHF Solutions
is headquartered in Minneapolis, Minn., with wholly-owned
subsidiaries in Australia and Ireland. The company has been listed
on the Nasdaq Capital Market since February 2012.
About the Aquadex System The Aquadex SmartFlow™
system delivers clinically proven therapy using a simple, flexible
and smart method of removing excess fluid from patients suffering
from hypervolemia (fluid overload). The Aquadex SmartFlow system is
indicated for temporary (up to 8 hours) or extended (longer than 8
hours in patients who require hospitalization) use in adult and
pediatric patients weighing 20 kg or more whose fluid overload is
unresponsive to medical management, including diuretics. All
treatments must be administered by a health care provider, within
an outpatient or inpatient clinical setting, under physician
prescription, both having received training in extracorporeal
therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements regarding the use of
Aquadex technology to treat heart failure patients. Forward-looking
statements are predictions, projections and other statements about
future events that are based on current expectations and
assumptions and, as a result, are subject to risks and
uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this
release, including, without limitation, those risk associated with
our ability to execute on our commercial strategy, the possibility
that we may be unable to raise sufficient funds necessary for our
anticipated operations, our post-market clinical data collection
activities, benefits of our products to patients, our expectations
with respect to product development and commercialization efforts,
our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual
property protection, our ability to integrate acquired businesses,
our expectations regarding anticipated synergies with and benefits
from acquired businesses, and other risks and uncertainties
described in our filings with the SEC. Forward-looking statements
speak only as of the date when made. CHF Solutions does not assume
any obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
CONTACTS
INVESTORS:Claudia Napal Drayton Chief Financial
Officer, CHF Solutions, Inc. 952-345-4205
Matt Bacso, CFAGilmartin Group LLC
MEDIA:Jessica
StebingHealth+Commerce260-336-6202
ir@chf-solutions.com
Matt.bacso@gilmartinir.com
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024